Literature DB >> 12419178

Hypertension and insulin disorders.

Michinori Imazu1.   

Abstract

Insulin resistance and/or compensatory hyperinsulinemia are associated with hypertension, obesity, dyslipidemia, and glucose intolerance. Insulin resistance and hyperinsulinemia are considered to increase blood pressure through sympathetic nervous system activation, renin-angiotensin system stimulation, and vascular smooth muscle cell proliferation. Leptin, magnesium ions, nitric oxide, endothelin, peroxisome proliferator-activated receptor gamma, and tumor necrosis factor-alpha also modulate blood pressure. Decreasing insulin resistance by lifestyle modification including diet, weight loss, and physical exercise has been shown to reduce blood pressure. Angiotensin-converting enzyme inhibitors have a beneficial effect on insulin resistance. On the other hand, the angiotensin II antagonist, losartan, does not affect insulin sensitivity. The selective alpha1-blockers have a favorable metabolic profile producing increases in insulin sensitivity. A short-acting type calcium channel blocker seems to decrease insulin sensitivity. On the other hand, long-acting type calcium channel blockers improve insulin sensitivity. Thiazide diuretics and most of the beta-blockers decrease insulin sensitivity. Vasodilatory beta-blockers have been reported to improve insulin sensitivity. Use of low-dose diuretics avoids the adverse effects seen with conventional doses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12419178     DOI: 10.1007/s11906-002-0029-y

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  53 in total

Review 1.  Insulin resistance and essential hypertension: pathophysiologic and therapeutic implications.

Authors:  A Santucci; C Ferri
Journal:  J Hypertens Suppl       Date:  1992-04

2.  The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats.

Authors:  K Higashiura; N Ura; T Takada; Y Li; T Torii; N Togashi; M Takada; H Takizawa; K Shimamoto
Journal:  Am J Hypertens       Date:  2000-03       Impact factor: 2.689

3.  Cross-talk between the insulin and angiotensin signaling systems.

Authors:  L A Velloso; F Folli; X J Sun; M F White; M J Saad; C R Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

4.  Serum-insulin in essential hypertension and in peripheral vascular disease.

Authors:  T A Welborn; A Breckenridge; A H Rubinstein; C T Dollery; T R Fraser
Journal:  Lancet       Date:  1966-06-18       Impact factor: 79.321

Review 5.  Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients.

Authors:  G R Sheinfeld; G L Bakris
Journal:  Am J Hypertens       Date:  1999-08       Impact factor: 2.689

6.  Metabolic precursors of hypertension. The San Antonio Heart Study.

Authors:  S M Haffner; H Miettinen; S P Gaskill; M P Stern
Journal:  Arch Intern Med       Date:  1996-09-23

Review 7.  Sodium-proton exchange and primary hypertension. An update.

Authors:  W Siffert; R Düsing
Journal:  Hypertension       Date:  1995-10       Impact factor: 10.190

8.  Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients.

Authors:  R Fogari; A Zoppi; L Corradi; P Lazzari; A Mugellini; P Lusardi
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

9.  Blood pressure response to hyperinsulinemia in salt-sensitive and salt-resistant rats.

Authors:  H Tomiyama; T Kushiro; H Abeta; H Kurumatani; H Taguchi; N Kuga; F Saito; F Kobayashi; Y Otsuka; K Kanmatsuse
Journal:  Hypertension       Date:  1992-11       Impact factor: 10.190

10.  Weight-reducing effects of the plasma protein encoded by the obese gene.

Authors:  J L Halaas; K S Gajiwala; M Maffei; S L Cohen; B T Chait; D Rabinowitz; R L Lallone; S K Burley; J M Friedman
Journal:  Science       Date:  1995-07-28       Impact factor: 47.728

View more
  5 in total

1.  Influence of resting energy expenditure on blood pressure is independent of body mass and a marker of sympathetic tone.

Authors:  David W Brock; Connie L Tompkins; Gordon Fisher; Gary R Hunter
Journal:  Metabolism       Date:  2011-08-04       Impact factor: 8.694

2.  Metallothionein alleviates cardiac contractile dysfunction induced by insulin resistance: role of Akt phosphorylation, PTB1B, PPARgamma and c-Jun.

Authors:  C X Fang; F Dong; B H Ren; P N Epstein; J Ren
Journal:  Diabetologia       Date:  2005-09-20       Impact factor: 10.122

Review 3.  Menopause, the metabolic syndrome, and mind-body therapies.

Authors:  Kim E Innes; Terry Kit Selfe; Ann Gill Taylor
Journal:  Menopause       Date:  2008 Sep-Oct       Impact factor: 2.953

4.  Comparative risk of new-onset diabetes mellitus for antihypertensive drugs in elderly: A Bayesian network meta-analysis.

Authors:  Jinhua Zhang; Aihua Tong; Yan Dai; Jie Niu; Fengquan Yu; Fangjiang Xu
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-06-26       Impact factor: 3.738

5.  Resting energy expenditure and systolic blood pressure relationships in women across 4.5 years.

Authors:  Neeraj Sriram; Gary R Hunter; Gordon Fisher; David W Brock
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-02-19       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.